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Abstract
Background: Alterations in the cadherin-catenin adhesion complexes are involved in tumor
initiation, progression and metastasis. However, the functional implication of distinct cadherin
types in breast cancer biology is still poorly understood.
Methods: To compare the functional role of E-cadherin and P-cadherin in invasive breast cancer,
we stably transfected these molecules into the MDA-MB-231 cell line, and investigated their effects
on motility, invasion and gene expression regulation.
Results: Expression of either E- and P-cadherin significantly increased cell aggregation and induced
a switch from fibroblastic to epithelial morphology. Although expression of these cadherins did not
completely reverse the mesenchymal phenotype of MDA-MB-231 cells, both E- and P-cadherin
decreased fibroblast-like migration and invasion through extracellular matrix in a similar way.
Moreover, microarray gene expression analysis of MDA-MB-231 cells after expression of E- and P-
cadherins revealed that these molecules can activate signaling pathways leading to significant
changes in gene expression. Although the expression patterns induced by E- and P-cadherin
showed more similarities than differences, 40 genes were differentially modified by the expression
of either cadherin type.
Conclusion: E- and P-cadherin have similar functional consequences on the phenotype and
invasive behavior of MDA-MB-231 cells. Moreover, we demonstrate for the first time that these
cadherins can induce both common and specific gene expression programs on invasive breast
cancer cells. Importantly, these identified genes are potential targets for future studies on the
functional consequences of altered cadherin expression in human breast cancer.
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Cadherins are integral membrane glycoproteins that
mediate calcium-dependent cell-cell adhesion [1]. Their
genes cluster in specific chromosomal regions, such as
human 16q22.1, where E-cadherin (CDH1) and P-cad-
herin (CDH3) genes are located [2]. Cadherins have
important differences in tissue expression and function
[3]. While E-cadherin (E-cadh) is expressed in the luminal
epithelial cells of the normal breast, P-cadherin (P-cadh)
expression is restricted to myoepithelial cells [3,4]. The
cytoplasmic domain of the cadherins interacts with the
catenins (α-, β-, γ-catenin and p120) to form the func-
tional adhesion complexes [5]. The catenins, in turn, are
able to mediate signaling pathways (such as the Wnt-
pathway) that control the expression of a number of genes
involved in tumorigenesis [6,7]. Alterations in the cad-
herin-catenin complexes are directly implicated in tumor-
igenesis and cancer progression [3,8,9]. E-cadherin gene
(CDH1) is considered a tumor and invasion suppressor
gene, since its down-regulation enhance cell migration
and promotes metastasis in a variety of cancer models
[10-13]. Reduction of E-cadherin expression is a frequent
event in various carcinoma types [3,8,9]. In breast cancer,
E-cadherin expression is reduced in about 50% of the duc-
tal tumors, and completely lost in the majority of lobular
carcinomas [14,15]. Loss of E-cadherin function in breast
tumor cells can be achieved by genetic (loss of heterozy-
gosity and inactivating mutations) and epigenetic (pro-
moter hypermethylation) alterations [14,16]. Moreover,
CDH1 can be transcriptionally repressed by a variety of
transcription factors, such as Snail (Snai1), Slug (Snai2)
and Twist, among others (reviewed in [17]). In some
tumor types and cellular models, loss of E-cadherin asso-
ciates to the process known as Epithelial-Mesenchymal
Transition (EMT), which is characterized by up-regulation
of mesenchymal markers (vimentin, fibronectin), modifi-
cation of actin cytoeskelton (induction of stress fibers and
focal adhesions), and acquisition of a fibroblastic, highly
invasive and metastatic phenotype [17,18].
Contrary to E-cadherin, P-cadherin positive expression in
breast carcinomas associates to unfavorable prognostic
factors, such as high grade and estrogen receptor negativ-
ity [19-22], but the functional role of P-cadherin in breast
tumorigenesis is poorly understood. Moreover, the exact
mechanisms by which the cadherins control tumor inva-
sion are not well defined.
To gain insights into the functional role of the E- and P-
cadherin in invasive breast cancer, we have analyzed the
effects of the ectopic expression of these cadherins on the
phenotype, migratory and invasive behavior of the MDA-
MB-231 cell line (hereafter referred as 231). Moreover, we
have characterized for the first time the transcriptional
changes modulated by E- and P-cadherin in these cells,
thus providing novel potential targets secondary to altered
cadherin expression in invasive breast cancer.
Methods
Cell Culture and Transfection
MDA-MB-231 and MCF7 breast cancer cell lines were
obtained from the American Type Culture Collection
(ATCC), and grown in DMEM medium, supplemented
with 10% fetal calf serum, and 1% penicillin-streptomy-
cin. To generate stable cell lines, cells were transfected
with the Dexamethasone (Dex)-inducible pLK-pac-based
vectors containing the complete human E-cadherin or P-
cadherin mRNAs [23] as well as the empty vector, using
TransFast Reagent (Promega). The plasmids were kindly
provided by Dr Albert B. Reynolds, (Nashville, USA), and
Keith R. Johnson (Omaha, USA). By puromycin selection
we isolated two clones for each condition: stably trans-
fected with E-cadherin (hereafter referred to as 231-E-
cadh), with P-cadherin (231-P-cadh) or containing the
empty vector (231-Control). To induce cadherin expres-
sion, cells were treated with 10 nM Dexamethasone for 24
hours. All experiments were performed using two clones
for each condition, and the presented data represents the
mean value of them.
Immunofluorescence
Cells grown on coverslips were fixed in either methanol (-
20°C) or 3.7% formaldehyde (30 min at room tempera-
ture) and then incubated with the primary antibodies at
the appropriate dilutions. The primary antibodies used
were: mouse anti-E-cadherin (clones HECD1 and 4A2C7,
from Zymed), anti-P-cadherin (BD Biosciences), anti β-
catenin (BD Biosciences), anti-paxillin (Calbiochem)
anti-vimentin (DAKO), anti-cytokeratins (AE1/AE3 from
Biomeda), and polyclonal rabbit anti-p120 (Sta Cruz Bio-
technology). The Alexa-488-coupled phalloidin (Molecu-
lar Probes, Eugene, OR) was used to stain actin
cytoskeleton. Secondary antibodies were Alexa488-cou-
pled anti-mouse, Alexa594-coupled anti-mouse or FITC-
coupled anti-rabbit (Molecular Probes). Cell nuclei were
stained using 4,6-diaminidino-2-phenylindole (DAPI)
(Molecular Probes). Staining was examined using a confo-
cal ultra-spectral-microscope (TCS-SP-2-AOBS-UV, Leica,
Wetzlar, Germany). Post-capture image analysis and
processing of confocal image stacks were performed using
the Leica Confocal software.
Western Blot
For western blotting, cells were washed with HMF Buffer
(Hepes buffer Mg2+ Free, 10 mM Hepes pH 7.4, 150 mM
NaCl, 1 mM CaCl2, 0.1% glucose) and proteins were
extracted using standard RIPA buffer containing protease
inhibitors. Polypeptides were transferred onto Immo-
bilon-P membranes (Millipore, Bedford, MA), and blots
were then incubated with anti-E-cadh (1:1000), anti-P-Page 2 of 14
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bodies for 1 hour. After washing, anti-mouse Ig HRP-con-
jugated secondary antibody (Amersham,
Buckinghamshire, UK) was then applied, and visualized
using the ECL chemiluminescence detection kit (Amer-
sham Biosciences, Uppsala, Sweden). For detection of E-
cadherin and P-cadherin proteins, blots were exposed 5
minutes, for alfa-tubulin 30 seconds. To compare the lev-
els of exogenous cadherins in 231-E-cadh and P-cadh
clones, band intensity was measured using ImageJ soft-
ware. Relative to alfa-tubulin (loading control), cadherin
expression after Dex induction was 0,98 and 0,92 for
231_E-cadherin clones, and 1,0 and 1,1 for P-cadherin
clones.
RNA extraction, amplification, labelling and microarray 
hybridization
Control cells (2 clones), as well as E-cadherin (2 clones)
and P-cadherin (2 clones) transfectans were treated with
Dex for 48 h and then grown without Dex for another 24
h, until the cells reached complete confluence. Moreover,
control cells were also grown in parallel for 72 h without
Dex (control untreated), until reached confluence. Total
RNAs for each condition were extracted using RNAesy
Extraction Kit (QIAGen), and subsequently amplified by
in vitro transcription using Megascript T7 protocol
(Ambion, Austin, TX), essentially as reported before
[24,25]. Amplified RNAs for the three control clones
treated with Dex were then mixed in equal proportions to
obtain a "Control-treated pool". This pool was labeled
with Cy3-dUTP fluorochrome (Amersham, Uppsala, Swe-
den) and subsequently used as the "reference sample" in
the hybridizations. Hybridizations were performed onto
the "CNIO Oncochip" cDNA microarray v 2.0, as
described previously [24,25].
Since the addition of Dex alone may alter the transcrip-
tional level of some genes, to identify the genes whose
expression was directly modified by E-cadherin or P-cad-
herin induction, we first hybridized (in quadruplicate)
Cy3-labelled-Control-treated pool against Cy5-Control-
untreated cells. The genes modulated by at least 2-fold
after Dex treatment in 231 control cells (data not shown)
were removed from the following analysis. After this filter-
ing, the amplified RNA from each of the 231_E-cadh and
231_P-cadh clones was labeled with Cy5 and then hybrid-
ized against a pooled RNA from the three Dex-treated con-
trol clones (reference sample). Two independent
hybridizations were performed for each clone, thus a total
of four experiments were performed for each condition
(E-cadh or P-cadh transfected cells). Microarray slides
were washed, dried, and then scanned in a Scanarray 5000
XL scanner (GSI Lumonics, Kanata, Ontario, Canada).
cDNA microarray data analysis
Data from the fluorescence intensity measurements of
each array experiment were processed using GenePix Pro
5.0 program (Axon Instruments, Inc., Union City, CA).
For statistical analysis, we selected genes with expressions
that differed by a factor of at least 2-fold with respect to
the control reference. A hierarchical clustering method
was applied to group of genes and samples on the basis of
the similarities in expression, and the unsupervised anal-
ysis were visualized using the SOTA and TreeView soft-
ware http://gepas3.bioinfo.cipf.es/cgi-bin/sotarray, http:/
/gepas3.bioinfo.cipf.es/cgi-bin/treeview, assuming Eucli-
dean distances between genes. Genes with potentially sig-
nificant changes in expression among the conditions were
identified using the POMELO program http://
pomelo2.bioinfo.cnio.es/. We tested the null hypothesis
of equal means among the three groups using ANOVA,
computing p-values using a permutation test. To select
differentially expressed genes, we adjusted for multiple
testing using the False Discovery Rate (FDR) method; we
report as differentially expressed genes with FDR adjusted
p-value < 0.15.
Protein interaction network
Modified genes found in the microarrays data were used
to produce a Protein-Protein Interaction (PPI) network for
the biological processes level. This analysis was carried out
using PathArchitect software v4.0 (Stratagene) incorporat-
ing information about these genes. Relevance networks
were built by using the algorithm indicated by the manu-
facturer.
Real time quantitative RT-PCR (qRT-PCR)
To validate data from cDNA microarrays, the expression
of selected genes was analyzed by qRT-PCR using gene-
specific TaqMan probes (Applied Biosystems, Foster City,
CA). Analysis was performed with the ABI PRISM 7700
Sequence Detection System Instrument and software
(Applied Biosystems), following the manufacturer's rec-
ommendations. Each reaction was performed in triplicate
from two cDNA dilutions. The internal standard human
beta-2 microglobulin gene (B2M; Applied Biosystems)
was used to normalize cDNA quantity. The amount of tar-
get gene and endogenous reference was determined using
the standard curve method. The standard curve was con-
structed by five-fold serial dilution of cDNA from a pool
of breast cancer tissues.
Cell aggregation Assay
MCF7 and 231 cells were tested for their ability to aggre-
gate in hanging drop suspension cultures, essentially as
described previously [23]. Briefly, cells were trypsinized,
counted, resuspended in DMEM medium with or without
10 nM Dex and plated in equal numbers as hanging drop
cultures. Cells were allowed to aggregate for 24 h at 37°C,Page 3 of 14
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gates prior to photography. The size of the particles was
measured using ImageJ 1.37c software and the mean par-
ticle area was represented for each of the experimental
conditions (n = 25).
In vitro wound healing assay
Equal number of cells was plated in triplicate on 60 mm
dishes. Cells were grown in culture media containing 10
nM Dex for 48 hours, until the cells reached the conflu-
ence. Monolayers of confluent cultures were lightly
scratched with a 20 μl-pipette tip and were photographed
by phase-contact microscopy at timed intervals for up to
24 hours. Quantification was done by measuring the
number of pixels in the wound area using Adobe® Pho-
toshop® and calculating the decrease in the area by sub-
tracting the number of pixels from the number of pixels in
the corresponding wound area at the 0 hour time point.
Additionally, wound healing assays were filmed by vide-
omicroscopy, using a confocal microscope (TCS-SP-2-
AOBS-UV, Leica). Videos were assembled using Adobe®
Premiere Pro 1.5 software.
Matrigel Transwell invasion assays
Cells were grown with 10 nM Dex during 48 h. To mini-
mize degradation of the cadherins, cells were shed using
EDTA-free Trypsin solution (Sigma), supplemented with
0.5 mM CaCl2. Cells were suspended in 500 μl DMEM
medium containing 0.1% FBS and 10 nM Dex. The ability
to invade through extracellular matrix was assessed by
Matrigel-coated Transwell invasion chambers of 8 μm
pore size (BD BioCoat Matrigel Invasion Chamber, Bec-
ton Dickinson) following manufacturer's instructions. 5 x
105 cells were plated on the Transwell, and the lower plate
contained DMEM 10% FBS as chemoattractant. After 24 h
cells in the upper filter were removed and the cells that
had traversed to the lower surface of the filter were fixed
and stained with DAPI. The number of migrated cells per
x20 field was analyzed microscopically and counted with
Scion Image Software (Scion Corporation). Experiments
were performed in duplicate, using two clones for each
condition.
Results
To assess the functional role of E-cadherin and P-cadherin
in invasive breast cancer, we first transfected 231 cells with
a constitutively activated expression vector (pCDNA3)
containing either the complete human E-cadherin or P-
cadherin cDNAs (kindly provided by Dr Setsuo Hiro-
hashi, Tokyo, Japan) [26]. However, we failed to obtain
stable clones expressing exogenous cadherins in the cell
membrane, and most of the cadherin protein remained
within the Golgi network (not shown). Moreover, because
high levels of E-cadherin are sometimes inhibitory to cell
growth [27,28], we then decided to use a Dexamethasone
(Dex)-inducible expression system (Plk-pac, kindly pro-
vided by Drs A. Reynolds, (Nashvile, USA), and Keith R.
Johnson (Omaha, USA)). This expression system has been
previously demonstrated to induce dose-dependent cad-
herin expression in 231 cells and other cadherin-deficient
cell lines [23]. After transfection, isolated 231-E-cadh and
231-P-cadh clones expressed low (basal) levels of E-cadh
or P-cadh, respectively, as determined by Western blot
(Figure 1A). In these cells, Dex treatment increased the
expression of the cadherins around 10-fold, but not
detectable expression was observed in control cells (Figure
1A). Measurement of band intensity demonstrated similar
expression of E-cadherin and P-cadherin in all the clones
used (see Materials and Methods).
Moreover, induction of E-cadherin or P-cadherin expres-
sion promoted a remarkable change in the morphology of
231 cells, which formed epithelium-like clusters, whereas
control clones maintained the fibroblastic appearance
(Figure 1B). By immunofluorescence, exogenous E-cadh
and P-cadh were mainly localized at the cell-to cell con-
tacts. Moreover, whereas in control cells beta-catenin was
expressed at low levels in the cell membrane and p120
accumulated in cytoplasm and nucleus [23], in cadherin-
expressing cells β-catenin was strongly expressed at cell-
cell contacts, and p120 shifted from the cytoplasm to the
membrane, where it co-localized with P-cadh or E-cadh
(Figure 1B). To demonstrate the functionality of these
adherens junctions, we performed a classic cell aggregation
assay. After 24 h of Dex induction, E- and P-cadh-express-
ing clones showed prominent aggregates, considerably
bigger than control clones, but comparable to those
formed by the E-cadherin-positive breast cancer cell line
MCF7 (Figure 1C). 231-E-cadh cells aggregates were
slightly bigger than those formed by 231-P-cadh cells, but
the differences were not statistically significant (Figure
1C).
We next studied whether expression of these cadherins
could completely reverse the fibroblastic phenotype of
231 cells. Expression of these cadherins did not signifi-
cantly modify actin cytoskeleton organization or the
number of focal adhesions (Figure 2). Moreover, no evi-
dent changes in the expression of EMT markers, such as
cytokeratins or vimentin were found (Figure 2), thus indi-
cating that E- and P-cadh expression is not sufficient to
induce a complete epithelial phenotype in these cells.
We then evaluated whether expression of these cadherins
altered cell motility using a classical wound-healing assay.
At early time points (10 h) we observed a significant
decrease in the migration ability of E-cadh and P-cadh-
positive cells compared to control cells (Figure 3A). How-
ever, both 231-E-cadh and P-cadh cells finally closed the
gap at similar time point as the control cells did (FigurePage 4 of 14
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clones were observed. Interestingly, using videomicros-
copy, we observed that control cells infiltrate the
wounded area as single cells (Figure 3A, marker by arrow;
and see Additional file 1), whereas E- or P-cadh cells
moved together as clusters, in a collective fashion (see
Additional files 2 and 3). Therefore, expression of E-cadh
or P-cadh alters the pattern of cell migration of 231 cells
by reducing their ability to infiltrate as single cells and
promoting an epithelial cell sheet-like movement.
Additionally, to assess the invasive capacities of cadherin-
transfected cells we performed in vitro invasion assays
using Matrigel-coated Transwell chambers. As shown in
Figure 3B, 231-E-cadh as well as 231-P-cadh cells invaded
through the extracellular matrix considerably less than
231-Control cells. No significant differences were
observed between 231-E-cadh and 231-P-cadh cells, thus
indicating that in the 231 cellular model both cadherins
show similar invasion suppressor abilities.
Since these cadherins were able to modify cellular mor-
phology, the migratory pattern, and invasive potential, it
raised the question of whether these molecules could
mediate their effects, at least in part, through regulation of
gene expression at the transcriptional level. To study if the
establishment of E-cadherin and P-cadherin-dependent
cell adhesion leads to regulation of gene expression, we
performed cDNA microarrays experiments (see detailed
procedures in Materials and Methods).
Using this approach, 126 clones (representing 107 known
genes) were found to be up- or down-regulated at least 2
fold in 231-E-cadh cells with respect to control cells,
whereas in 231-P-cadh cells 98 clones (79 genes) were
modulated (Table 1). According to data bases (Gene
Cards; http://www.genecards.org) these genes belonged
to a wide a range of biological functions, including signal
transduction and growth factors (VEGFC, FGFR4), cell
cycle (CCNA2), cell adhesion and extracellular matrix
(CDH4, COL12A1), or cytokines and inflammation
(IL24), among others. This indicates that in addition to
their role in cell-adhesion, E-cadh and P-cadh have a sig-
nificant impact on the overall genetic program of breast
cancer cells. Table 2 shows a selection of genes, the com-
plete list of genes, arranged by function is provided in
Additional file 4.
Moreover, to identify possible signaling pathways regu-
lated by E- and P-cadherin, we have generated potential
protein-protein interaction networks with cadherin-regu-
lated genes at the biological processes level (Additional
files 5 and 6). This analysis demonstrated that some cad-
herin-regulated genes are interconnected, thus providing
numerous cross-talks among distinct biological processes.
Then, to visually compare the expression profiles modu-
lated by each cadherin type we performed an unsuper-
vised hierarchical clustering. As shown in Figure 4A, the
four hybridizations of 231-E-cadh cells grouped together
in a branch separated from that of 231-P-cadh cells, sug-
gesting that differences in their expression profiles may
exist. However, using this clustering method more simi-
larities than differences were observed between the
expression profiles of 231-E-cadh and 231-P-cadh cells.
To better establish which genes were differentially and
specifically regulated by each cadherin type, we performed
a supervised analysis using the POMELO tool. Using this
ANOVA-based supervised approach, 46 clones (40 genes)
were identified as differentially expressed with a signifi-
cant association (FDR-adjusted p value < 0.15) between
the two cadherin types (Figure 4B; complete list of genes
in Additional file 4). Therefore, these data indicate that E-
and P-cadherin induce a common gene expression pro-
gram, but they can also specifically modify a subset of
genes.
Finally, real-time quantitative RT-PCR analysis (qRT-PCR)
on selected genes validated the microarrays data (Figure
4C). Specifically, we confirmed the down-regulation of
the Rho GDP dissociation inhibitor beta gene (ARHGDIB)
in both 231-E-cadh and 231-P-cadh cells (although to a
lesser extent in 231-E-cadh cells), and the over-expression
of Vascular endothelial growth factor C (VEGFC) in cells
expressing either cadherin type. Moreover qRT-PCR anal-
ysis also confirmed the differential regulation of Matrix
Exogenous expression of E- and P-cadherin promotes formation of functional adherens junctions and morphological changes in 231 cellsFigure 1 (s e previous page)
Exogenous expression of E- and P-cadherin promotes formation of functional adherens junctions and morpho-
logical changes in 231 cells. A: Western blot showing E- and P-cadherin expression before (-) and after (+) addition of Dex-
amethasone in 231 clones. MCF7 and BT549 cells were used as controls for endogenous expression of E- and P-cadherin, 
respectively. B: E- or P-cadherin expression promotes epitheloid morphology (first column, bright field) and recruits the cat-
enins (p120 and beta-catenin) to the adherens junctions (immunofluorescence, columns two to four). C: E- or P-cadherin 
expression enhances cell aggregation. Left pictures show representative examples of cellular aggregation in each condition ("-", 
before and "+" after addition of Dex). E-cadherin positive MCF7 cells were used as control. Right: Quantification of mean par-
ticle size. Each bar represents mean ± SEM size (measured in pixels) of cell aggregates (n = 25, for each condition). Mean differ-
ences were compared by Student's t test (* indicates differences statistically significant p < 0.05; NS, not significant).Page 6 of 14
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Expression of E- or P-cadherin does not completely reverse the mesenchymal phenotype of 231 cellsFigure 2
Expression of E- or P-cadherin does not completely reverse the mesenchymal phenotype of 231 cells. First row: 
Double immunofluorescence of E- or P-cadherin (Alexa-594, red) and actin cytoskeleton (Phalloidin-Alexa-488, green). Second 
row: Focal adhesions (arrows) co-stained with Phalloidin (green) and anti-paxillin (red). Note that no evident changes in the 
number or organization of focal adhesions are seen among the different conditions. Third and fourth rows: expression of the 
mesenchymal marker vimentin and the epithelial marker cytokeratin.
BMC Cancer 2009, 9:74 http://www.biomedcentral.com/1471-2407/9/74Metalloproteinase 14 gene (MMP14); down-regulated in
231-P-cadh but not in 231-E-cadh cells.
Discussion
Abnormal expression of diverse cadherin types has been
widely reported in breast cancer [3,8,9], but the causes
and functional consequences of these alterations are not
fully understood. Our data indicate that exogenous
expression of either E- or P-cadherin in highly invasive
MDA-MB-231 cells promotes a switch from fibroblastic to
epitheloid morphology. However, although these cadher-
ins are unable to completely reverse the mesenchymal
phenotype in invasive breast cancer cells (as evidenced by
the maintenance of multiple actin stress fibers, focal adhe-
sions, and the expression of vimentin [[29,30] and current
work]), we show here that either E- or P-cadherin reduces
the ability of 231 cells to infiltrate as single cells, by pro-
moting an epithelial-like collective cell migration. Moreo-
ver, we confirmed the invasion suppressor activity of E-
cadherin [30-32], and demonstrate that P-cadherin can
E- and P-cadherin modify the migratory and invasive behaviour of 231 cellsFigure 3
E- and P-cadherin modify the migratory and invasive behaviour of 231 cells. A: Study of cell migration by wound 
healing assay. Left pictures show that control cells migrate as single cells (arrow) whereas 231_E-cadh and 231_P-cadh cells 
migrate as clusters. Right: Cell migration was quantified by measuring the wounded area (in pixels) that was covered by the 
cells in the indicated time points. Each bar represents mean ± SEM of four independent experiments. B: Invasion ability 
through extracellular matrix (Matrigel) assessed by Transwell assays. Left: Representative images showing the number of 
invaded cells (nuclei stained by DAPI) after 24 hours. Right: Quantification of invasion. Each bar represents mean number ± 
SEM of invaded cells for each condition (four independent experiments). Mean differences were compared by Student's t test 
(* indicates differences statistically significant p < 0.05; NS, not significant).Page 8 of 14
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way as reported in lung cancer [33] and melanoma cells
[34]. However, the anti-invasive potential of E- or P-cad-
herin in cancer cells may vary among the different cancer
cell types and biological contexts. For instance, a high
level of exogenous P-cadherin over-expression, or the
presence of endogenous classical cadherins might be
responsible, in part, for the pro-invasive or pro-migratory
effect of P-cadherin observed in epithelial breast MCF7/
AZ or pancreatic Panc-1 cells [35,36]. It should be recalled
that the different types of cadherins compete for a limited
pool of catenins (especially p120), thus provoking cad-
herin endocytosis [37]. To minimize this competitive
effect we have used the 231 cell line, which lacks classical
cadherins [38], and an inducible system that allowed
expressing the exogenous E- or P-cadherin to levels similar
to the endogenous expression in other breast cancer cell
lines.
Assuming the particularities of the different cellular mod-
els, increasing evidences indicate that the roles of the cad-
herins in carcinogenesis and tumor progression, do not
solely lie on their adhesive function [30-32,39], but also
depend on their interaction with other molecules (such as
cytoskeletal components, integrins, and growth-factor
receptors, among others) and signaling pathways
[6,7,40,41]. Therefore, it has been proposed that the cad-
herins may participate in a variety of signaling pathways
leading to modulation of specific genes at the transcrip-
tional level, and as a consequence, regulation of impor-
tant cellular functions, including invasion, motility, or
cell cycle [8,13].
To demonstrate that the establishment of E-cadherin and
P-cadherin-dependent cell adhesion leads to regulation of
gene expression we performed a comprehensive gene
expression analysis using large-scale cDNA microarrays.
We detected the transcriptional modification (at least 2-
fold) of 107 and 79 genes by E-cadherin and P-cadherin,
respectively. The genes belonged to a variety of biological
functions such as cell motility and invasion (Cdc42,
ITGB2), cell cycle (EGR1, RRM2) or signal transduction
(VEGFC), indicating that expression of E-cadh and P-cadh
in breast cancer cells have a significant impact on their
overall genetic program. Importantly, some of these cad-
herin-regulated genes may be functionally interconnected
(Additional files 5 and 6) thus providing potential signal-
ing pathways involved in distinct biological processes.
It is worth noting that a substantial number of genes were
modified in a similar way by both cadherin types, suggest-
ing the existence of a core "cadherin-associated" genetic
program that would support the analogous functional
consequences of expressing of E- or P-cadherin in 231
cells. Nonetheless, gene expression profiling analyses also
demonstrated that each cadherin type can also specifically
modify a subset of genes, thus indicating that they can reg-
ulate both common and specific biological functions in
invasive breast carcinomas.
Focusing on cell motility and invasion, we observed that
in 231 cells E- and/or P-cadherin regulate the expression
of some genes associated to integrin signaling (ITGB2, β2
integrin; ILK, Integrin-linked kinase), intercellular adhe-
sion (cadherins 4 and 18), extracellular remodeling
(MMP14, SERPINE2), and cytoskeleton (Cdc42, ARH-
GDIB). Similarly, E-cadherin has been reported to tran-
scriptionally regulate a variety of integrins and matrix
metalloproteases (MMP1, MMP2, MMP3, MMP14 and
TIMP-1) in other cancer models [42-45]. This indicates
the existence of a functional crosstalk between cadherin,
integrin signaling, and extracellular matrix remodeling in
human tumors. This crosstalk, which can be controlled at
the transcriptional level by the cadherins, may underlie
the anti-invasive and anti-metastatic effect of the E-cad-
herin (and probably P-cadherin) in a variety of carcino-
mas. Consistently, E-cadherin loss increases the
expression of α2, α3 and β1-integrins, MMP2 and MMP9
metalloproteases, and subsequently leads to an enhanced
invasion and metastatic ability in transformed keratinoc-
ytes [45,46]. The exact mechanisms and signaling path-
ways leading to regulation of invasion by the cadherins
are still to be clarified. Here we identify ARHGDIB (Rho
Table 1: Functional grouping of genes modulated at least 2 fold 
in E-cadherin or P-cadherin-expressing cells with respect to 
control cells.
231-E-cadherin 231-P-cadherin
Gene function Up Down All Up Down All
Basic cellular functions 15 8 23 13 8 21
Cell cycle and Apoptosis 3 14 17 2 4 6
Signal Transduction 6 14 20 9 6 15
Adhesion & ECM 1 8 9 2 3 5
Cytokines & Immune 1 7 8 2 1 3
Metabolism 7 2 9 4 2 6
Transcription related 0 6 6 4 4 8
Motility & Cytoskeleton 4 3 7 4 1 5
Unknown function 3 5 8 2 8 10
TOTAL 40 67 107 42 37 79Page 9 of 14
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gene as a candidate gene potentially involved in this proc-
ess. This gene, which encodes for a regulator of actin
cytoskeleton, is transcriptionally down-regulated after E-
and P-cadherin induction in 231 cells. Importantly, previ-
ous reports have demonstrated that inhibition of ARH-
GDIB in invasive breast cancer cell lines significantly
reduces their invasive behavior through regulation of β1-
integrin signaling [47].
Finally, it is important to highlight that the effect of the
cadherins on the overall gene expression program of can-
cer cells is highly dependent on the cellular type and the
biological context. Thus, cadherin regulation of specific
transcriptional factors may depend on the activation of
other signaling pathways, or the presence of additional
molecular alterations. For instance, exogenous E-cadherin
expression considerably alters the global gene expression
profile of colon cancer cells with activated Wnt pathway,
mainly by controlling the nucleo-cytoplasmic pool of
beta-catenin. However, E-cadherin expression has a mod-
est transcriptional effect on human fibroblasts [48]. More-
over, as mentioned before, E-cadherin alone is not able to
completely reverse the mesenchymal phenotype of inva-
sive breast cancer cells, or the full EMT induced by Snail in
MDCK cells [49]. By contrast, in immortalized human
mammary epithelial cells, shRNA-mediated E-cadherin
knockdown resulted in complete EMT through the modu-
lation of a large set of genes, whereas introduction of a
truncated dominant-negative E-cadherin construct failed
to do so [39]. Interestingly, in this cellular model, the
induction of EMT after E-cadherin depletion seemed to be
partially mediated by Twist and ZEB1, two strong E-cad-
herin repressors. Additionally, in the MDA-MB-435 breast
cancer cell line the presence of wild-type or mutant E-cad-
herin proteins leads to the differential regulation of a vari-
Table 2: Selection of genes modulated at least 2 fold after E-cadherin and/or P-cadherin induction with respect to control cells.
GenBank accession # Gene Symbol Description Mean E-cadh Mean P-cadh
Cellular adhesion and Extracellular Matrix
AA865745 CDH18 Cadherin 18, type 2 2.07 1.09
AI003692 CDH4 Cadherin 4, R-cadherin (retinal) 2.03 -1.20
H11732 CLECSF2 C-type lectin domain 2, member B 4.45 3.86
AA478481 COL12A1 Collagen, type XII, alpha 1 2.90 2.01
AW467461 ITGB2 Integrin beta 2 -2.28 -1.98
N33214 MMP14 Matrix metalloproteinase 14 -1.24 -2.46
N59721 SERPINE2 Plasminogen activator inhibitor type 1 member 2 -1.38 -2.87
Motility and cytoskeleton
CR936693 ADD1 Adducin 1 (alpha) -3.93 -4.66
N49912 ARHGDIB Rho GDP dissociation inhibitor beta -2.41 -6.07
AA009697 CDC42 Cell division cycle 42 2.03 1.73
AA148200 ILK Integrin-linked kinase-2 2.09 1.66
Signal transduction
AI140863 EDN2 Endothelin 2 3.12 1.10
AA446994 FGFR4 Fibroblast growth factor receptor 4 -1.17 -2.06
N20338 HGS Hepatocyte growth factor-regulated tyrosine kinase substrate 2.16 1.53
AA026831 KDR Kinase insert domain receptor 3.33 1.09
W55872 NFKBIA NFKB inhibitor, alpha 2.25 1.66
H26426 PTPRM PTP, receptor M 1.23 -2.05
H07991 VEGFC Vascular endothelial growth factor C 2.20 2.61
Transcription related
H21041 ATF3 Activating transcription factor 3 2.31 1.65
AA026120 BHLHB2 Basic helix-loop-helix domain containing class B2 1.04 -2.11
AA868008 HIST1H4C Histone 1, H4c 2.50 2.15
Cell Cycle and apoptosis
AA489752 CCNG2 Cyclin G2 2.18 -1.73
AA486628 EGR1 Early growth response 1 4.20 1.53
N94468 JUNB Homo sapiens jun B proto-oncogene 2.05 1.04
AA826373 RRM2 Ribonucleotide reductase M2 3.30 5.53
AA039640 WEE1 WEE1 homolog 4.78 2.24
Cytokines and immune response
W46900 CXCL1 Chemokine (C-X-C motif) ligand 1 3.56 2.58
N31850 IL24 Interleukin 24 2.88 -2.16
Genes are grouped by function and arranged by alphabetic order. Genes differentially expressed with statistically significance (FDR < 0.15) between 
E-cadherin and P-cadherin are highlighted in bold letter. Mean E-cadh: mean gene expression value in two E-cadherin clones; Mean P-cadh: mean 
gene expression value in two P-cadherin clones. Negative value indicates that gene expression is down-regulated with respect to control cells.Page 10 of 14
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observed here that TCF3 mRNA is down-regulated in 231
cells expressing P-cadherin but not E-cadherin. Together
all these data suggest that the levels of different cadherin
types or the presence of abnormal (mutant) cadherins
might lead to the differential regulation of EMT transcrip-
tion factors in breast cancer cells. These factors, in turn,
might control cadherin transcriptional levels, thereby gen-
erating an auto-regulatory loop. However, this hypothesis
has not been tested yet.
Conclusion
Our data indicate that in fibroblastic invasive breast can-
cer cells, both E- and P-cadherin have similar effects on
the cell phenotype and the migratory and invasive behav-
ior. Moreover, the establishment of E- and P-cadherin-
E- and P-cadherin modulate transcriptional changesFigure 4
E- and P-cadherin modulate transcriptional changes. A: Unsupervised hierarchical clustering of the gene expression 
patterns induced by E- or P-cadherin expression. Columns represent microarray experiments, and rows gene expression of 
the 149 genes modified at least two-fold with respect to control cells. Intensity of color is a function of the gene expression 
level as depicted in the scale bar. B: Identification of genes differentially expressed (with a statistical significance of FDR < 0.15) 
between 231_E-cadh and 231_P-cadh cells. C: Validation of microarray data of selected genes by qRT-PCR. Bars represent 
mean gene expression ± SEM (mRNA levels relative to control B2M transcript) from four different experiments.ARHGDIB is 
down-regulated and VEGFC is over-expressed in 231_E-Cadh and 231_P-cadh cells compared to control cells. MMP14 is down-
regulated only in 231_P-cadh clones.Page 11 of 14
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BMC Cancer 2009, 9:74 http://www.biomedcentral.com/1471-2407/9/74dependent cell adhesion leads to regulation of a common
gene expression program, and modulation of particular
genes that may potentially underlie their anti-invasive
effect. In addition, they can also specifically modify a sub-
set of genes, thus suggesting that they could mediate both
common and specific biological functions in invasive
breast carcinomas. The identified genes are potential tar-
gets for future studies on the functional consequences of
altered cadherin expression in human breast cancer.
Abbreviations
E-cadh: E-cadherin; P-cadh: P-cadherin; Dex: Dexametha-
sone.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DS carried out molecular, cell biology, and microarray
experiments, participated in the design of the study and
drafted the manuscript. JP participated in the design of the
study and drafted the manuscript. MH-R participated in
microarray experiments and data analysis. GG partici-
pated in the protein interaction networks. AC participated
in the study design and drafted the manuscript. GM-B
conceived the study, performed microarray data analysis,
and drafted the manuscript. All authors read and
approved the final manuscript.
Additional material
Acknowledgements
The authors thank to Drs Albert Reynolds (Nashville, USA), Keith R John-
son (Omaha, USA), and Setsuo Hirohashi (Tokyo, Japan) for providing 
cDNAs and plasmids. We are also grateful to Diego Megías (CNIO, Spain) 
and Dr Ester Martín-Villar (CSIC, Spain) for helping with cell migration and 
invasion assays. This work has been supported by grants from the Fun-
dación Mutua Madrileña (2006) and SAF2007-63075 to GMB; SAF 2007-
63051 to AC; PI051890 and SAF2004-08258-C02-01 to JP. David Sarrió 
currently is a recipient of a Marie Curie Intra-European Fellowship of the 
European Commission (PIEF-GA-2008-221083). Gema Moreno-Bueno is a 
junior investigator of the "Ramón y Cajal Program" of the Spanish Ministry 
of Education and Science (2004).
References
1. Takeichi M: Cadherin cell adhesion receptors as a morphoge-
netic regulator.  Science 1991, 251:1451-1455.
2. Nollet F, Kools P, van Roy F: Phylogenetic analysis of the cad-
herin superfamily allows identification of six major sub-
families besides several solitary members.  J Mol Biol 2000,
299(3):551-572.
3. Potter E, Bergwitz C, Brabant G: The cadherin-catenin system:
implications for growth and differentiation of endocrine tis-
sues.  Endocr Rev 1999, 20(2):207-239.
4. Gumbiner BM: Cell adhesion: the molecular basis of tissue
architecture and morphogenesis.  Cell 1996, 84(3):345-357.
5. Gumbiner BM: Regulation of cadherin adhesive activity.  J Cell
Biol 2000, 148(3):399-404.
6. Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt
signaling in cancer.  Biochim Biophys Acta 2003, 1653(1):1-24.
Additional file 1
Wound healing assay 231-control cells. Wound healing assay showing 
that 231_control cells infiltrate the wounded area as single cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S1.mov]
Additional file 2
Wound healing assay 231-E-cadherin cells. Wound healing assay show-
ing that 231_E-cadh cells invade the wounded area as cell clusters in a 
collective fashion.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S2.mov]
Additional file 3
Wound healing assay 231-P-cadherin cells. Wound healing assay show-
ing that 231_P-cadh cells invade the wounded area as cell clusters in a 
collective fashion.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S3.mov]
Additional file 4
Complete list of genes modulated by E-cadherin and/or P-cadherin (at 
least 2 fold with respect to control cells) in 231 cells. Genes modulated 
by E-cadherin and/or P-cadherin are grouped by function and arranged by 
alphabetic order. The genes differentially expressed with statistically sig-
nificance (FDR < 0.15) between E-cadherin and P-cadherin are high-
lighted in red bold letter.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S4.doc]
Additional file 5
Potential signaling networks mediated by E-cadherin-regulated genes 
at the biological process level. Genes modulated by E-cadherin may be 
involved in crosstalk among diverse biological processes. Green: down-reg-
ulated genes; Red: up-regulated genes. Semi-transparent nodes were 
inferred by the relevance networks algorithm due to their statistical rele-
vance according to the user-defined network components.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S5.pdf]
Additional file 6
Potential signaling networks mediated by P-cadherin-regulated genes 
at the biological process level. Genes modulated by P-cadherin may be 
involved in crosstalk among diverse biological processes. Green: down-reg-
ulated genes; Red: up-regulated genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-74-S6.pdf]Page 12 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:74 http://www.biomedcentral.com/1471-2407/9/747. Reynolds AB, Carnahan RH: Regulation of cadherin stability and
turnover by p120ctn: implications in disease and cancer.
Semin Cell Dev Biol 2004, 15(6):657-663.
8. Beavon IR: The E-cadherin-catenin complex in tumour metas-
tasis: structure, function and regulation.  Eur J Cancer 2000,
36:1607-1620.
9. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M: Defec-
tive E-cadherin/catenin complexes in human cancer.  Virchows
Arch 2001, 439(6):725-751.
10. Christofori G, Semb H: The role of the cell-adhesion molecule
E-cadherin as a tumour-suppressor gene.  Trends Biochem Sci
1999, 24(2):73-76.
11. Guilford P: E-cadherin downregulation in cancer: fuel on the
fire?  Mol Med Today 1999, 5(4):172-177.
12. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F: Genetic
manipulation of E-cadherin expression by epithelial tumor
cells reveals an invasion suppressor role.  Cell 1991,
66(1):107-119.
13. Wijnhoven BP, Dinjens WN, Pignatelli M: E-cadherin-catenin cell-
cell adhesion complex and human cancer.  Br J Surg 2000,
87(8):992-1005.
14. Berx G, Van Roy F: The E-cadherin/catenin complex: an impor-
tant gatekeeper in breast cancer tumorigenesis and malig-
nant progression.  Breast Cancer Res 2001, 3(5):289-293.
15. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A,
Cano A, Martin-Perez J, Gamallo C, Palacios J: Cytoplasmic locali-
zation of p120ctn and E-cadherin loss characterize lobular
breast carcinoma from preinvasive to metastatic lesions.
Oncogene 2004, 23(19):3272-3283.
16. Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M,
Herman JG, Gamallo C, Esteller M, Palacios J: Epigenetic and
genetic alterations of APC and CDH1 genes in lobular breast
cancer: relationships with abnormal E-cadherin and catenin
expression and microsatellite instability.  Int J Cancer 2003,
106(2):208-215.
17. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in
tumour progression: an alliance against the epithelial pheno-
type?  Nat Rev Cancer 2007, 7(6):415-428.
18. Thiery JP: Epithelial-mesenchymal transitions in tumour pro-
gression.  Nat Rev Cancer 2002, 2(6):442-454.
19. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt
FC: P-cadherin overexpression is an indicator of clinical out-
come in invasive breast carcinomas and is associated with
CDH3 promoter hypomethylation.  Clin Cancer Res 2005,
11(16):5869-5877.
20. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA: P-
cadherin expression in breast carcinoma indicates poor sur-
vival.  Cancer 1999, 86(7):1263-1272.
21. Kovacs A, Dhillon J, Walker RA: Expression of P-cadherin, but
not E-cadherin or N-cadherin, relates to pathological and
functional differentiation of breast carcinomas.  Mol Pathol
2003, 56(6):318-322.
22. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Pala-
cios J: The prognostic significance of P-cadherin in infiltrating
ductal breast carcinoma.  Mod Pathol 2001, 14(7):650-654.
23. Thoreson MA, Anastasiadis PZ, Daniel JM, Ireton RC, Wheelock MJ,
Johnson KR, Hummingbird DK, Reynolds AB: Selective uncoupling
of p120(ctn) from E-cadherin disrupts strong adhesion.  J Cell
Biol 2000, 148(1):189-202.
24. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla
SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, et al.: Genetic pro-
filing of epithelial cells expressing e-cadherin repressors
reveals a distinct role for snail, slug, and e47 factors in epi-
thelial-mesenchymal transition.  Cancer Res 2006,
66(19):9543-9556.
25. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S,
Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Mat-
ias-Guiu X, et al.: Differential gene expression profile in
endometrioid and nonendometrioid endometrial carci-
noma: STK15 is frequently overexpressed and amplified in
nonendometrioid carcinomas.  Cancer Res 2003,
63(18):5697-5702.
26. Shimoyama Y, Yoshida T, Terada M, Shimosato Y, Abe O, Hirohashi
S: Molecular cloning of a human Ca2+-dependent cell-cell
adhesion molecule homologous to mouse placental cad-
herin: its low expression in human placental tissues.  J Cell Biol
1989, 109(4 Pt 1):1787-1794.
27. Gottardi CJ, Wong E, Gumbiner BM: E-cadherin suppresses cel-
lular transformation by inhibiting beta-catenin signaling in
an adhesion-independent manner.  J Cell Biol 2001,
153(5):1049-1060.
28. Sasaki CY, Lin H, Morin PJ, Longo DL: Truncation of the extracel-
lular region abrogrates cell contact but retains the growth-
suppressive activity of E-cadherin.  Cancer Res 2000,
60(24):7057-7065.
29. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH,
Petersen OW, Turley EA, Bissell MJ: Phenotypic reversion or
death of cancer cells by altering signaling pathways in three-
dimensional contexts.  J Natl Cancer Inst 2002, 94(19):1494-1503.
30. Wong AS, Gumbiner BM: Adhesion-independent mechanism
for suppression of tumor cell invasion by E-cadherin.  J Cell Biol
2003, 161(6):1191-1203.
31. Chen H, Paradies NE, Fedor-Chaiken M, Brackenbury R: E-cadherin
mediates adhesion and suppresses cell motility via distinct
mechanisms.  J Cell Sci 1997, 110(Pt 3):345-356.
32. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner
D, Birchmeier W: E-cadherin-mediated cell-cell adhesion pre-
vents invasiveness of human carcinoma cells.  J Cell Biol 1991,
113(1):173-185.
33. Foty RA, Steinberg MS: Measurement of tumor cell cohesion
and suppression of invasion by E- or P-cadherin.  Cancer Res
1997, 57(22):5033-5036.
34. Van Marck V, Stove C, Bossche K Van Den, Stove V, Paredes J,
Haeghen Y Vander, Bracke M: P-cadherin promotes cell-cell
adhesion and counteracts invasion in human melanoma.  Can-
cer Res 2005, 65(19):8774-8783.
35. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L,
Mareel M, Bracke M, Schmitt F: P-cadherin is up-regulated by the
antiestrogen ICI 182,780 and promotes invasion of human
breast cancer cells.  Cancer Res 2004, 64(22):8309-8317.
36. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohi-
gashi H, Ishikawa O, Katagiri T, Nakamura Y: P-cadherin/CDH3
promotes motility of pancreatic cancer cells by interacting
with p120ctn and activating rho-family GTPases.  Cancer Res
2005, 65(8):3092-3099.
37. Maeda M, Johnson E, Mandal SH, Lawson KR, Keim SA, Svoboda RA,
Caplan S, Wahl JK 3rd, Wheelock MJ, Johnson KR: Expression of
inappropriate cadherins by epithelial tumor cells promotes
endocytosis and degradation of E-cadherin via competition
for p120(ctn).  Oncogene 2006, 25(33):4595-4604.
38. Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA,
Byers SW: Cadherin-11 is expressed in invasive breast cancer
cell lines.  Cancer Res 1999, 59(4):947-952.
39. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg R: Loss
of E-cadherin promotes metastasis via multiple downstream
transcriptional pathways.  Cancer Res 2008, 68(10):3645-3654.
40. Cavallaro U, Christofori G: Cell adhesion and signalling by cad-
herins and Ig-CAMs in cancer.  Nat Rev Cancer 2004,
4(2):118-132.
41. Christofori G: Changing neighbours, changing behaviour: cell
adhesion molecule-mediated signalling during tumour pro-
gression.  Embo J 2003, 22(10):2318-2323.
42. Andersen H, Mejlvang J, Mahmood S, Gromova I, Gromov P, Lukani-
din E, Kriajevska M, Mellon JK, Tulchinsky E: Immediate and
delayed effects of E-cadherin inhibition on gene regulation
and cell motility in human epidermoid carcinoma cells.  Mol
Cell Biol 2005, 25(20):9138-9150.
43. Kohya N, Kitajima Y, Jiao W, Miyazaki K: Effects of E-cadherin
transfection on gene expression of a gallbladder carcinoma
cell line: repression of MTS1/S100A4 gene expression.  Int J
Cancer 2003, 104(1):44-53.
44. Laux H, Tomer R, Mader MT, Smida J, Budczies J, Kappler R, Hahn H,
Blochinger M, Schnitzbauer U, Eckardt-Schupp F, et al.: Tumor-asso-
ciated E-cadherin mutations do not induce Wnt target gene
expression, but affect E-cadherin repressors.  Lab Invest 2004,
84(10):1372-1386.
45. Margulis A, Zhang W, Alt-Holland A, Crawford HC, Fusenig NE, Gar-
lick JA: E-cadherin suppression accelerates squamous cell car-
cinoma progression in three-dimensional, human tissue
constructs.  Cancer Res 2005, 65(5):1783-1791.Page 13 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:74 http://www.biomedcentral.com/1471-2407/9/74Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
46. Zhang W, Alt-Holland A, Margulis A, Shamis Y, Fusenig NE, Rodeck
U, Garlick JA: E-cadherin loss promotes the initiation of squa-
mous cell carcinoma invasion through modulation of
integrin-mediated adhesion.  J Cell Sci 2006, 119(Pt 2):283-291.
47. Zhang Y, Zhang B: D4-GDI, a Rho GTPase regulator, promotes
breast cancer cell invasiveness.  Cancer Res 2006, 66:5592-5598.
48. Kuphal F, Behrens J: E-cadherin modulates Wnt-dependent
transcription in colorectal cancer cells but does not alter
Wnt-independent gene expression in fibroblasts.  Exp Cell Res
2006, 312(4):457-467.
49. Ohkubo T, Ozawa M: The transcription factor Snail downregu-
lates the tight junction components independently of E-cad-
herin downregulation.  J Cell Sci 2004, 117(Pt 9):1675-1685.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/74/prepubPage 14 of 14
(page number not for citation purposes)
